British Journal of Cancer
December 18, 2020
Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomarker to DDA and/or DNA damage-response inhibitor (DDRi) therapies.
In this work, Genedata Screener was used to analyze compound combination activity (synergy), using the HSA dose-additivity model available in Screener.